S&P 500   4,272.48 (-0.36%)
DOW   33,344.84 (-0.49%)
QQQ   359.69 (+0.40%)
AAPL   173.39 (+1.27%)
MSFT   318.77 (+0.96%)
META   304.13 (+1.31%)
GOOGL   133.22 (+1.80%)
AMZN   128.85 (+1.36%)
TSLA   249.37 (-0.34%)
NVDA   447.92 (+2.97%)
NIO   8.75 (-3.21%)
BABA   86.24 (-0.58%)
AMD   102.92 (+0.10%)
T   14.78 (-1.60%)
F   12.27 (-1.21%)
MU   67.74 (-0.43%)
CGC   0.73 (-6.75%)
GE   108.81 (-1.57%)
DIS   81.36 (+0.38%)
AMC   7.96 (-0.38%)
PFE   33.66 (+1.48%)
PYPL   58.39 (-0.12%)
NFLX   379.15 (+0.41%)
S&P 500   4,272.48 (-0.36%)
DOW   33,344.84 (-0.49%)
QQQ   359.69 (+0.40%)
AAPL   173.39 (+1.27%)
MSFT   318.77 (+0.96%)
META   304.13 (+1.31%)
GOOGL   133.22 (+1.80%)
AMZN   128.85 (+1.36%)
TSLA   249.37 (-0.34%)
NVDA   447.92 (+2.97%)
NIO   8.75 (-3.21%)
BABA   86.24 (-0.58%)
AMD   102.92 (+0.10%)
T   14.78 (-1.60%)
F   12.27 (-1.21%)
MU   67.74 (-0.43%)
CGC   0.73 (-6.75%)
GE   108.81 (-1.57%)
DIS   81.36 (+0.38%)
AMC   7.96 (-0.38%)
PFE   33.66 (+1.48%)
PYPL   58.39 (-0.12%)
NFLX   379.15 (+0.41%)
S&P 500   4,272.48 (-0.36%)
DOW   33,344.84 (-0.49%)
QQQ   359.69 (+0.40%)
AAPL   173.39 (+1.27%)
MSFT   318.77 (+0.96%)
META   304.13 (+1.31%)
GOOGL   133.22 (+1.80%)
AMZN   128.85 (+1.36%)
TSLA   249.37 (-0.34%)
NVDA   447.92 (+2.97%)
NIO   8.75 (-3.21%)
BABA   86.24 (-0.58%)
AMD   102.92 (+0.10%)
T   14.78 (-1.60%)
F   12.27 (-1.21%)
MU   67.74 (-0.43%)
CGC   0.73 (-6.75%)
GE   108.81 (-1.57%)
DIS   81.36 (+0.38%)
AMC   7.96 (-0.38%)
PFE   33.66 (+1.48%)
PYPL   58.39 (-0.12%)
NFLX   379.15 (+0.41%)
S&P 500   4,272.48 (-0.36%)
DOW   33,344.84 (-0.49%)
QQQ   359.69 (+0.40%)
AAPL   173.39 (+1.27%)
MSFT   318.77 (+0.96%)
META   304.13 (+1.31%)
GOOGL   133.22 (+1.80%)
AMZN   128.85 (+1.36%)
TSLA   249.37 (-0.34%)
NVDA   447.92 (+2.97%)
NIO   8.75 (-3.21%)
BABA   86.24 (-0.58%)
AMD   102.92 (+0.10%)
T   14.78 (-1.60%)
F   12.27 (-1.21%)
MU   67.74 (-0.43%)
CGC   0.73 (-6.75%)
GE   108.81 (-1.57%)
DIS   81.36 (+0.38%)
AMC   7.96 (-0.38%)
PFE   33.66 (+1.48%)
PYPL   58.39 (-0.12%)
NFLX   379.15 (+0.41%)
NASDAQ:AGEN

Agenus (AGEN) Stock Forecast, Price & News

$1.04
-0.09 (-7.92%)
(As of 01:45 PM ET)
Compare
Today's Range
$1.03
$1.13
50-Day Range
$1.12
$1.56
52-Week Range
$1.03
$3.37
Volume
1.64 million shs
Average Volume
4.81 million shs
Market Capitalization
$394.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.10

Agenus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
639.7% Upside
$8.10 Price Target
Short Interest
Bearish
7.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$280,747 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.77) to ($0.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

277th out of 969 stocks

Biological Products, Except Diagnostic Industry

41st out of 161 stocks


AGEN stock logo

About Agenus (NASDAQ:AGEN) Stock

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN Price History

AGEN Stock News Headlines

Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's
A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>
Agenus (AGEN) Receives a Buy from Robert W. Baird
Agenus to cut 25% staff as lead program takes priority
Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's
A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>
B.Riley Financial Sticks to Their Buy Rating for Agenus (AGEN)
Lexington biotech lays off 91 as it narrows focus
Robert W. Baird Keeps Their Buy Rating on Agenus (AGEN)
Agenus Inc. Q2 Earnings Summary
Agenus Reports Second Quarter 2023 Results
Agenus Q2 2023 Earnings Preview
Agenus (AGEN) Receives a Buy from Jefferies
B.Riley Financial Reaffirms Their Buy Rating on Agenus (AGEN)
See More Headlines
Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Company Calendar

Last Earnings
8/08/2023
Today
10/02/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AGEN
CUSIP
00847G70
Employees
533
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.10
High Stock Price Forecast
$8.30
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+616.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-220,070,000.00
Net Margins
-276.92%
Pretax Margin
-276.92%

Debt

Sales & Book Value

Annual Sales
$99.36 million
Book Value
($0.18) per share

Miscellaneous

Free Float
361,353,000
Market Cap
$428.92 million
Optionable
Optionable
Beta
1.42
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 70)
    Founder, Exec. Chairman & CEO
    Comp: $1.31M
  • Ms. Christine M. Klaskin (Age 57)
    VP of Fin., Principal Financial Officer & Principal Accounting Officer
    Comp: $379.83k
  • Dr. Steven J. O'Day M.D. (Age 61)
    Ph.D., Chief Medical Officer
    Comp: $867.12k
  • Craig Winter
    Chief Information Officer
  • Mr. Zack Armen
    Head of Investor Relations
  • Ms. Robin E. Abrams J.D. (Age 59)
    Chief Legal Officer
  • Ms. Stephanie Fagan
    Chief Communications Officer
  • Ms. Tracy Mazza Clemente
    Chief People Officer
  • Ms. Julie DeSander
    Chief Bus. Officer
  • Mr. Dhan Chand
    Scientific Director & Head of Drug Discovery













AGEN Stock - Frequently Asked Questions

Should I buy or sell Agenus stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings
or view top-rated stocks.

What is Agenus' stock price forecast for 2023?

4 equities research analysts have issued 1 year target prices for Agenus' stock. Their AGEN share price forecasts range from $8.00 to $8.30. On average, they anticipate the company's share price to reach $8.10 in the next year. This suggests a possible upside of 616.8% from the stock's current price.
View analysts price targets for AGEN
or view top-rated stocks among Wall Street analysts.

How have AGEN shares performed in 2023?

Agenus' stock was trading at $2.40 on January 1st, 2023. Since then, AGEN shares have decreased by 52.9% and is now trading at $1.13.
View the best growth stocks for 2023 here
.

When is Agenus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our AGEN earnings forecast
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). The biotechnology company had revenue of $25.30 million for the quarter, compared to analysts' expectations of $23.98 million. During the same quarter in the prior year, the firm earned ($0.17) EPS.

What ETF holds Agenus' stock ?

WisdomTree BioRevolution Fund holds 20,765 shares of AGEN stock, representing 1.09% of its portfolio.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?
What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $1.13.

How much money does Agenus make?

Agenus (NASDAQ:AGEN) has a market capitalization of $428.92 million and generates $99.36 million in revenue each year. The biotechnology company earns $-220,070,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Agenus have?

The company employs 533 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200.

This page (NASDAQ:AGEN) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -